Articles

Clinical Trial Data Sharing in Europe: EMA's New Open Science Mandate

The EMA's new Open Science mandate aims to improve clinical trial data sharing across Europe, fostering transparency and collaboration in drug development.

Phase 1 Trial Evolution: EMA’s New Safety Monitoring Requirements Explained

This article delves into the EMA's updated safety monitoring requirements for Phase 1 trials, focusing on DrugX's role in cancer treatment and patient safety.

Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO

This article delves into the latest EU guidelines and ESMO recommendations on treatment sequencing for non-small cell lung cancer (NSCLC), highlighting osimertinib's role.

EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe

The EMA Cell Therapy Framework aims to enhance CAR-T therapy access in Europe, potentially transforming treatment options for hematological malignancies.

EU vs US Clinical Trial Protocols: Key Differences in Design & Timelines

This article delves into the critical differences in clinical trial design and timelines between the EU and US, focusing on DrugX for ConditionY.

EGFR Inhibitors Market Access in Europe: Launch Strategies & Challenges

This article delves into the market access strategies and challenges for EGFR inhibitors in Europe, crucial for advancing lung cancer therapies.

NICE Technology Appraisals & G-BA Assessments for EMA-Approved Oncology Drugs 2026

This article delves into the NICE technology appraisals and G-BA assessments for EMA-approved oncology drugs in 2026, highlighting their impact on treatment access.

PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies

This article delves into PRAC's assessment of safety signals related to bispecific antibodies, focusing on their efficacy and safety in treating hematologic malignancies.

Continuous Manufacturing in Pharmaceuticals: EU Regulatory Insights & Innovation

Discover how continuous manufacturing is transforming pharmaceutical production, with key EU regulatory insights and innovations for drug safety and efficiency.

European Academic Clinical Trials: Funding and Success Rates Analysis 2024-2026

This analysis delves into the funding landscape and success rates of European academic clinical trials, focusing on drug development for chronic diseases between 2024 and 2026.

NICE Technology Appraisals 2026: Impact on EU Pharmaceutical Market Access

NICE Technology Appraisals 2026 will significantly reshape the landscape for cancer drug access in the EU, impacting market dynamics and patient outcomes.

MHRA Post-Brexit Drug Approval: Key Divergences from EMA in Oncology

This article examines the MHRA's post-Brexit drug approval framework for oncology, focusing on significant divergences from the EMA's processes.

EU Pharmaceutical Legislation Reform: Impact on Generic and Biosimilar Markets 2026-27

The upcoming EU Pharmaceutical Legislation Reform will significantly reshape the landscape for generic and biosimilar drugs, influencing market dynamics through 2026-27.

EMA Accelerated Assessment Program: Impact on Oncology Drug Approval Timelines

The EMA's Accelerated Assessment Program significantly shortens oncology drug approval timelines, improving patient access to vital treatments such as Keytruda.

EMA Conditional Approval Pathway: Linvoseltamab and Oncology Access in EU

This article delves into the EMA's Conditional Approval Pathway, focusing on Linvoseltamab and its impact on oncology access across the European Union.

CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments

This article examines the varying assessments of CAR-T therapies' cost-effectiveness by EU HTA bodies, highlighting implications for cancer treatment.

MHRA post-Brexit regulatory pathways: What You Need to Know

Explore the essential MHRA post-Brexit regulatory pathways for drug approval, ensuring compliance and understanding for pharmaceutical professionals.

Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework

The EMA's Hybrid Trial Framework revolutionizes drug development by integrating real-world evidence, improving outcomes for patients with chronic conditions.

EU HTA Radioligand Therapy Assessment: Price, Access & Challenges

This article delves into the EU HTA's evaluation of radioligand therapy for prostate cancer, highlighting pricing, access issues, and the challenges in the healthcare landscape.

CHMP Positive Opinions Diabetes Drugs: What You Need to Know Q3 2026

In Q3 2026, the CHMP issued positive opinions for key diabetes drugs, including Ozempic and Jardiance, highlighting advancements in diabetes management.